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ABSTRACT
Between 1996 and 2002, 103 hospitalised patients yielding one or more clinical isolates of extended-
spectrum b-lactamase-producing Escherichia coli (ESBL-EC) were identified. A significant increase was
observed in the incidence of ESBL-EC colonisation or infection during the study period (1.65
episodes ⁄ 100 000 patient-days in 1996 to 12.6 episodes ⁄ 100 000 patient-days in 2002; p 0.01). Infection
developed in 70 (68%) patients (75 episodes), with surgical site (44%) and urinary tract (17%) infections
being the most frequent. Pulsed-field gel electrophoresis showed extensive clonal diversity among the
isolates. A case-control study and multivariate analysis identified female gender (OR 2.1; p 0.01), use of
a nasogastric tube (OR 3.5; p 0.001) and previous antibiotic therapy (OR 3.9; p < 0.001) as independent
variables associated with acquisition of ESBL-EC. The study demonstrated a progressive increase in the
number of ESBL-EC isolates in a non-epidemic setting. Most cases of ESBL-EC colonisation or infection
occurred in hospitalised patients exposed to invasive procedures and antibiotic pressure.
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INTRODUCTION
During the past two decades, strains that produce
extended-spectrum b-lactamases (ESBLs) have
emerged among the Enterobacteriaceae [1].
Although ESBL production was described ini-
tially, and is most prevalent, in Klebsiella pneumo-
niae [2–5], Escherichia coli strains producing ESBLs
have become increasingly common since their
first description in 1987 [6]. Research has tended
to focus on the nosocomial spread of ESBL-
producing K. pneumoniae, which is usually related
to overuse of oxyimino-b-lactams and inadequate
hospital hygiene [4,5]. Several studies on the
epidemiological behaviour of K. pneumoniae have
also reported the occurrence of ESBL-producing
E. coli (ESBL-EC) strains [7–9], but the differences
between the two pathogens mean that combined
analyses of this kind may not be ideal for
studying the clinical epidemiology of ESBL-EC.
The emergence of ESBL-EC has important
clinical and therapeutic implications, given that
E. coli are frequent aetiological agents of both
hospital- and community-acquired infections,
and also because therapeutic options against
ESBL-producing strains are severely limited
[10–12]. A better understanding of the epidemi-
ological factors predisposing to ESBL-EC infec-
tions, and the identification of patients at risk, is
vital for the prevention of spread and to ensure
careful selection of patients for appropriate
empirical treatment. Following a progressive
increase in the number of ESBL-EC isolates from
patients hospitalised in the Hospital Universitari
de Bellvitge (Barcelona, Spain), the present study
aimed to identify the risk-factors for ESBL-EC
strain acquisition.
PATIENTS AND METHODS
Setting and study design
The study was carried out in the Hospital Universitari de
Bellvitge, a 1000-bed teaching hospital for adult patients (mean
annual admission of 24 000 patients) that provides acute
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medical (cardiology, internal medicine, infectious diseases,
endocrinology, pneumology, nephrology and gastroenterol-
ogy) and surgical (digestive surgery, cardiovascular, urology,
thoracic, otorhinolaryngology, traumatology, maxillo-facial,
plastic and gynaecology) care, but does not admit paediatric,
obstetric or burn unit patients.
A case-control study was performed to define the risk-
factors for ESBL-EC strain acquisition. Cases were defined as
hospitalised patients identified prospectively from whom
ESBL-EC was isolated during the study period (January 1996
to December 2002). Potential controls were recruited from
the cohort of hospitalised patients, and were defined as
patients from whom ESBL-EC was not isolated, regardless of
the type of clinical sample or whether the culture was
positive or negative for other pathogens. Controls were
selected randomly from the cohort of hospitalised patients,
with the same date of admission and with a hospital stay
equal to or longer than that of the cases [13]. Case and
control patients were not otherwise matched. One control
was selected for each case.
Data collected concerning patients were: demographic
characteristics, underlying diseases, immunosuppressive ther-
apy, previous surgery, intensive care unit admission, stay in a
long-term care facility, medical procedures (intravascular
catheters, urinary catheters, endotracheal tubes and nasogas-
tric tubes), presence of decubitus ulcers and previous antibiotic
use.
Definitions
ESBL-EC colonisation or infection was considered to be
hospital-acquired if the isolate was obtained ‡ 48 h after
admission and if no evidence of colonisation or infection was
present upon admission. Immunosuppressive therapy was
defined as administration of chemotherapy, radiotherapy
and ⁄ or immunosuppressive drugs in the 30-day period
preceding isolation of ESBL-EC. Previous surgery was
defined as a surgical procedure that occurred during the
previous 6 months. Previous antibiotic use was defined as
administration of antibiotic therapy for >48 h during the
previous 3 months; antibiotic therapy was also recorded for
different groups of antibiotics, i.e., quinolones, b-lactam ⁄
b-lactamase inhibitors, carbapenems and oxyimino b-lactams.
Previous hospital admission was defined as admission to
acute hospital care for >2 days in the 6-month period before
isolation of ESBL-EC. Clinical assessment was according to
CDC criteria [14]; patients with samples from any body site
that were positive for ESBL-EC, but without related signs or
symptoms of infection, were considered to be colonised.
Microbiological studies
Identification and susceptibility tests were performed using
the MicroScan system (Dade Behring, West Sacramento, CA,
USA). NCCLS criteria were used to define susceptibility or
resistance to antimicrobial agents [15]. ESBL production was
detected by the double-disk synergy test [16] and by Etests for
ESBLs (AB Biodisk, Solna, Sweden).
Isoelectric focusing of b-lactamases was performed as
described previously [5] using a PhastSystem apparatus
(Amersham, Little Chalfont, UK) and polyacrylamide gels
with a pH range of 3–9 (PhastGel 3–9; Amersham). pIs were
determined by comparison with those for a set of b-lactamases
with known pIs. Genes encoding the SHV (blaSHV) and CTX-M
(blaCTX-M-9 and blaCTX-M-10) b-lactamase families were detected
by PCR as described previously [17].
Pulsed-field gel electrophoresis was performed in a CHEF-
DR III apparatus (Bio-Rad Laboratories, Richmond, CA, USA),
following restriction with XbaI (New England Biolabs, Boston,
MA, USA), with pulse times of 1–30 s and a voltage of 6 V ⁄ cm
for 23 h at 14C, as described previously [5].
Statistical analysis
Contingency tables were analysed by two-tailed chi-square
tests. Continuous variables were compared by the t-test.
Univariate analysis was performed to determine the signifi-
cance of risk-factors for ESBL-EC acquisition, with p 0.05
considered to be statistically significant. Multivariate analysis
was performed with an unconditional stepwise logistic regres-
sion model to assess the independence of statistically signifi-
cant variables in the univariate analysis. The annual incidence
was calculated according to the number of episodes of
infection (some patients had more than one infection) or
colonisation ⁄ 100 000 patient-days. Statistical analyses were
performed using SPSS ⁄PC v. 11.0 software (SPSS Inc., Chicago,
IL, USA).
RESULTS
During the study period, 103 hospitalised patients
with one or more clinical samples positive for
ESBL-EC were identified. A gradual increase in
the incidence of ESBL-EC colonisation or infection
during the study period was observed (1.65
episodes ⁄ 100 000 patient-days in 1996 vs. 12.6
episodes ⁄ 100 000 patient-days in 2002; p 0.01).
The demographic and epidemiological character-
istics of the 103 patients are summarised in
Table 1. Thirty patients had received previous
immunosuppressive therapy, including anti-can-
cer chemotherapy (14 patients; nine with haema-
tological malignancies, five with solid tumours),
steroids (eight patients; two with bronchopulmo-
nary disease, two with a brain tumour, four with
autoimmune disease), and steroids and immuno-
suppressive drugs (eight transplanted patients).
Seventy (68%) of the patients with ESBL-EC
isolates were infected, with 75 documented epi-
sodes of infection; these comprised 33 surgical site
infections, 13 urinary tract infections, ten primary
bacteraemias (two catheter-related and eight of
unknown origin), eight spontaneous episodes of
peritonitis in cirrhotic patients, six respiratory
tract infections, three cases of ascending cholan-
gitis, and two non-surgical abscesses.
Of the 103 patients with ESBL-EC isolates, 33
had been admitted previously to an intensive care
unit, but none had been admitted previously to a
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long-term care facility. The attributable mortality
rate for ESBL-EC infection was 16% (11 of 70
infected patients). Significant associations follow-
ing comparison of the 103 case patients with the
control patients are summarised in Table 2. The
independent risk-factors identified by an uncon-
ditional logistic regression model in which ESBL-
EC colonisation or infection was the dependent
variable, with adjustment for age, gender, under-
lying disease, use of a nasogastric tube and
previous antibiotic therapy, are shown in Table 3.
All the isolates had a positive double-disk
synergy test result, and should therefore be
considered to be resistant to penicillins, first-,
second-, third- and fourth-generation cephalospo-
rins and aztreonam, despite apparent in-vitro
susceptibility to some of these agents for certain
isolates (53% had a ceftazidime MIC < 2 mg ⁄L;
42% had an aztreonam MIC < 2 mg ⁄L; and 23%
had a cefotaxime MIC < 2 mg ⁄L). All isolates
were susceptible to cefoxitin (MIC £ 8 mg ⁄L),
while 66% of isolates had amoxycillin–clavulanic
acid and piperacillin–tazobactam MICs
£ 8 ⁄ 4 mg ⁄L and £ 16 mg ⁄L, respectively. The
percentage of isolates showing resistance to the
other antibiotics tested was: gentamicin, 13%;
tobramycin, 8%; ciprofloxacin, 50%; and
co-trimoxazole, 62%. None of the ESBL-EC
isolates showed resistance to carbapenems or
amikacin.
Table 4 summarises the epidemiological and
microbiological data for 33 randomly selected
ESBL-EC isolates that were studied in detail.
Eighteen isolates produced a single b-lactamase,
while 15 isolates produced two b-lactamases with
different pIs. Eighteen isolates were positive for
blaCTX-M-9 (pI 8.1) and six were positive for blaSHV.
Resistance to ciprofloxacin and co-trimoxazole
were the most common associated resistances.
Pulsed-field gel electrophoresis revealed 27
different genotypes among 28 ESBL-EC isolates
from 28 patients. The ESBL-EC isolates from the
remaining five patients were non-typeable by
pulsed-field gel electrophoresis.
DISCUSSION
This study focused on the analysis of hospitalised
patients who were colonised or infected by ESBL-
producing strains of E. coli. The data provide
evidence for some specific features that differen-
tiate between the acquisition of ESBL-EC and that
of ESBL-producing K. pneumoniae (ESBL-KP).
There was extensive clonal diversity among the
ESBL-EC isolates throughout the period of the
study. Although the possibility of plasmid trans-
mission between isolates was not studied, the
Table 1. Demographic and epidemiological characteristics
of 103 patients yielding isolates of Escherichia coli produ-
cing extended-spectrum b-lactamases (ESBLs)
Characteristics
ESBL-producing E. coli patients
(n = 103)
Age, mean years ± SD (range) 60.0 ± 16 (18–91)
Gender, n (%)
Male 50 (48.5)
Female 53 (51.5)
Co-morbid conditiona, n (%) 93 (90)
Hepatic dysfunction, n 16
Malignancy, n 28
Diabetes, n 3
Organ transplantation, n 8
Immunosuppressive therapy, n 30
Other, n 46
Previous surgery, n (%) 72 (70)
Previous hospital admission, n (%) 46 (45)
Previous antibiotics, n (%) 84 (82)
Fluoroquinolones 20 (19)
b-Lactamase inhibitor 47 (46)
Carbapenems 8 (8)
Oxyimino-b-lactams 33 (32)
Clinical assessment, n (%)
Colonisation 33 (32)
Infection 70 (68)
aSome patients had more than one co-morbid condition.
Table 2. Risk-factors (univariate analysis) for acquisition
of Escherichia coli producing extended-spectrum b-lacta-
mases
Characteristics
Cases
n = 103
Controls
n = 103 p
Age, mean years ± SD 62.13 ± 15.80 59.29 ± 15.25 NS
Gender (M ⁄ F) 50 ⁄ 53 63 ⁄ 40 0.06
Underlying diseases 93 82 0.03
Immunosuppressive therapy 30 24 NS
Previous hospital admission 46 36 NS
Previous intensive care unit admission 33 16 < 0.01
Previous surgery 72 53 < 0.01
Venous catheter 91 74 < 0.01
Urinary catheter 60 38 < 0.01
Mechanical ventilation 26 9 < 0.01
Nasogastric tube 39 13 < 0.01
Decubitus ulcers 10 3 0.04
Previous antibiotic therapy 84 53 < 0.01
Fluoroquinolones 20 19 NS
b-Lactamase inhibitor 47 22 < 0.01
Carbapenems 8 5 NS
Oxyimino-b-lactams 33 19 0.02
NS, not significant.
Table 3. Independent risk-factors for acquisition of
Escherichia coli producing extended-spectrum b-lactamases
Risk-factor Adjusted OR (95% CI) p
Female gender 2.1 (1.14–4.04) 0.01
Nasogastric tube 3.5 (1.68–7.61) 0.001
Previous antibiotic therapy 3.9 (2.03–7.81) < 0.001
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data did not suggest that cross-transmission
among patients was the cause of the increase in
the frequency of ESBL-EC isolates. The outbreak
of ESBL-KP reported previously occurred in
intensive care units as primary bacteraemias [5].
However, the types of infection associated with
ESBL-EC in this study were quite similar to those
usually reported for non-ESBL-EC isolates. A
miscellany of infections was detected, including
surgical site and urinary tract infections; of note
was the observation of several patients with liver
cirrhosis and spontaneous peritonitis.
There was a high prevalence (50%) of ESBL
type CTX-M-9, as also found by other studies
Table 4. Epidemiological and microbiological characteristics of 33 isolates of Escherichia coli producing extended-
spectrum, b-lactamases
Patient Age ⁄Gender Source Year Ward
b-Lactamase
pI by IEF
PCR results MIC (mg ⁄L)
Associated
resistancesblaSHV blaCTX-M-9 blaCTX-M-10 A ⁄C FOX CTX CAZ AZT
1 58 ⁄ F Blood 1998 Haematology 5.4 – – – 8 ⁄ 4 8 0.5 8 1 Cip
SxT
2 41 ⁄ F Wound 1998 ICU 7.6 + – – 16 ⁄ 8 8 0.5 32 1 None
3 69 ⁄ F Urine 1998 Urology 8.1 – + – 4 ⁄ 2 8 >32 1 1 None
4 55 ⁄M Blood 1999 Haematology 5.4 – – – 8 ⁄ 4 8 0.5 >32 16 Gen
Tob
Cip
5 78 ⁄ F Ascitic fluid 1999 Gastroenterology 5.4, 8.1 – + – 16 ⁄ 8 8 >32 2 16 Cip
SxT
6 54 ⁄M Blood 1999 Haematology 5.4, 8.1 – + – 8 ⁄ 4 8 >32 1 8 Cip
SxT
7 72 ⁄M Blood 1999 ICU 5.4, 8.1 – + – 8 ⁄ 4 8 >32 8 8 Cip
SxT
8 79 ⁄M Urine 1999 Surgery 5.4, 8.1 – + – 4 ⁄ 2 8 >32 1 1 SxT
9 81 ⁄M Blood 2000 Surgery 7.6 + – – 16 ⁄ 8 8 0.5 2 1 None
10 69 ⁄M Urine 2000 Urology 8.1 – + – 16 ⁄ 8 8 >32 >32 >16 Cip
SxT
11 78 ⁄ F Urine 2000 Traumatology 5.4, 8.1 – + – 4 ⁄ 2 8 >32 1 1 Cip
SxT
12 58 ⁄ F Blood 2000 Haematology 5.4, 8.2 + – – >16 ⁄ 8 8 >32 >32 >16 Cip
SxT
13 38 ⁄M Blood 2000 Neurology 8.2 – – – 4 ⁄ 2 8 8 1 8 Cip
SxT
14 58 ⁄M Blood 2000 ICU 8.1 – + – 8 ⁄ 4 8 >32 16 16 Cip
SxT
15 78 ⁄ F Wound 2000 Neurosurgery 8.1 – – – 8 ⁄ 4 8 >32 8 >16 Cip
SxT
16 41 ⁄M Blood 2001 Internal Medicine 5.4, 8.1 – + – 8 ⁄ 4 8 >32 1 8 Cip
SxT
17 75 ⁄ F Sputum 2001 ICU 7.6 + – – 16 ⁄ 8 8 0.5 8 1 None
18 68 ⁄M Blood 2001 Urology 5.4, 8.1 – + – 8 ⁄ 4 8 >32 1 >16 Cip
SxT
19 72 ⁄ F Blood 2001 ICU 5.4, 7.4 – – – 16 ⁄ 8 8 2 1 1 Cip
20 71 ⁄ F Blood 2001 Urology 5.4 – – – 4 ⁄ 2 8 >32 8 >16 Cip
SxT
21 84 ⁄ F Urine 2001 Urology 5.4, 8.1 – + – 8 ⁄ 4 8 >32 2 16 Cip
SxT
22 18 ⁄M Urine 2001 Urology 7.6 + – – 16 ⁄ 8 8 >32 >32 >16 SxT
23 86 ⁄ F Urine 2001 ICU 8.1 – + – 4 ⁄ 2 8 >32 1 8 Cip
24 22 ⁄ F Blood 2001 Haematology 8.2 – – – 4 ⁄ 2 8 >32 >16 >16 Cip
25 68 ⁄M Sputum 2001 ICU 8.1 – + – 4 ⁄ 2 8 >32 1 8 Cip
26 74 ⁄M Wound 2001 Surgery 5.4, 8.1 – + – 4 ⁄ 2 8 32 1 2 Gen
Tob
Cip
SxT
27 75 ⁄ F Bile 2002 Surgery 7.4 – – – >16 ⁄ 8 8 2 1 1 Gen
Tob
Cip
SxT
28 76 ⁄M Urine 2002 Neurology 5.4. 8.1 – + – 8 ⁄ 4 8 >32 2 8 Cip
SxT
29 74 ⁄M Ascitic fluid 2002 Surgery 5.4, 8.1 – + – 4 ⁄ 2 8 >32 1 8 Cip
SxT
30 34 ⁄ F Blood 2002 Surgery 8.2 – – – 4 ⁄ 2 8 >32 2 16 Cip
31 68 ⁄M Sputum 2002 ICU 6.2, 8.2 + – – 4 ⁄ 2 8 >32 >32 >16 None
32 37 ⁄ F Blood 2002 Internal Medicine 8.1 – + – 4 ⁄ 2 8 >32 1 8 Cip
SxT
33 78 ⁄ F Urine 2002 Urology 5.4, 8.1 – + – 4 ⁄ 2 8 >32 1 1 Cip
SxT
A ⁄C, amoxycillin–clavulanic acid (2:1); FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; AZT, aztreonam; Cip, ciprofloxacin; Gen, gentamicin; Tob, tobramycin; SxT, co-
trimoxazole; ICU, intensive care unit.
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performed in the same geographical area [12,18].
CTX-M-type ESBLs confer a high level of resist-
ance to cefotaxime, but are less efficient against
ceftazidime. However, clinical experience does
not support the routine use of ceftazidime, and
the options for empirical treatment of ESBL-EC
infections are limited to carbapenems and amika-
cin. Another feature that distinguished between
ESBL-EC and ESBL-KP infections was the higher
rate of susceptibility to b-lactam ⁄ b-lactamase
inhibitor combinations [5]; these combinations
may therefore be efficacious for the treatment of
some ESBL-EC infections. A high rate of resist-
ance (50%) to fluoroquinolones was observed,
and a similar association between fluoroquino-
lone resistance and ESBL production has been
reported previously [19,20]. Rates of fluoroquino-
lone resistance among E. coli isolates that do not
produce ESBLs are 25% in Hospital Universitari
de Bellvitge, and no evidence for clusters of
genetically related strains or major consumption
of quinolones was found that would account for
the higher rate of 50% in the case patients.
Several risk-factors for ESBL-EC acquisition
were identified, and all were related to invasive
procedures and antibiotic pressure. Unlike the
epidemiology of nosocomial outbreaks of
ESBL-KP, in which use of oxymino-b-lactams
probably plays the most important role, treatment
with other antibiotics seemed to be a significant
risk-factor for the selection of ESBL-EC isolates.
Patients may be asymptomatic carriers of
ESBL-EC [21], and ESBL-EC of clinical significance
may be selected in those patients who require a
large number of invasive procedures and in whom
antibiotic therapy is overused. It should be noted
that consumption of antibiotics, as well as anato-
mical and physiological host factors, gastrointes-
tinal surgery, abnormal gastrointestinal motility
or artificial nutrition, reduce resistance to coloni-
sation [22]. Impairment of colonisation resistance
may enable the outgrowth of resistant strains in
patients who are colonised in their digestive
tract. Overall, medical procedures and large-scale
use of antibiotics seem to be the major risk-factors
for non-epidemic acquisition of ESBL-EC.
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